Clinical Trials Directory

Trials / Completed

CompletedNCT01606254

A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia

A Repeated Dose Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
56 (actual)
Sponsor
Janssen Pharmaceutical K.K. · Industry
Sex
All
Age
20 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and safety of paliperidone palmitate in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).

Detailed description

This is a multicenter (when more than one hospital or medical school team work on a medical research study), open-label (all people know the identity of the intervention), randomized (the study drug is assigned by chance), parallel-group (Each group of participants will be treated at the same time), comparison study to assess the pharmacokinetics and safety of paliperidone palmitate (study medication) in participants with schizophrenia. The study comprises a 64-day Treatment period and a 155-day Follow-up period. The participants will be randomly assigned to one of the four study groups. The study medication will be administered on Days 1, 8, 36 and 64. Pharmacokinetics of the study medication will be assessed as primary outcome. Participants' safety will be monitored throughout the study.

Conditions

Interventions

TypeNameDescription
DRUGPaliperidone palmitatePaliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.

Timeline

Start date
2007-01-01
Primary completion
2008-04-01
Completion
2008-04-01
First posted
2012-05-25
Last updated
2013-06-05
Results posted
2013-04-18

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT01606254. Inclusion in this directory is not an endorsement.